High expression of SOX30 is associated with favorable survival in human lung adenocarcinoma.
In our previous study, we had identified SOX30 as a novel tumor suppressor that acts through direct regulation of p53 transcription in human lung cancer. Here, we sought to determine the clinical relevance of SOX30 expression in a series of surgically-resected non-small cell lung cancer (NSCLC) patients. Analysis of SOX30 expression and clinico-pathologic features reveal a significant correlation of SOX30 expression with histological type (n = 220, P = 0.008) and clinical stage (n = 220, P = 0.024). Kaplan-Meier analysis indicates an association of high SOX30 expression with better prognosis in NSCLC patients (n = 220, P = 0.007). Via multivariate Cox-regression analysis, SOX30 expression is revealed to be an independent prognostic factor for overall survival (OS) of NSCLC patients (n = 220, P = 0.014, hazard ratio (HR) = 0.816). In particular, SOX30 is a favorable and independent prognostic factor in one main subtype of NSCLC, lung adenocarcinoma (ADC) patients (n = 150, P = 0.000, HR = 0.405), but not in another main subtype of NSCLC, squamous cell carcinoma patients. Furthermore, high expression of SOX30 represents a favorable and independent factor for the prognosis of ADC patients at clinical stage II (P = 0.013), with positive lymph node (P = 0.003), at histological grade 2 (P = 0.000) or grade 3 (P = 0.025). In summary, SOX30 expression represents an important prognostic factor for survival time in ADC patients.
Institute of Toxicology, College of Preventive Medicine, Third Military Medical University.|Key Laboratory of Medical Protection for Electromagnetic Radiation, Ministry of Education of China, Chongqing 400038, PR China.
Fei
F
Han
Institute of Toxicology, College of Preventive Medicine, Third Military Medical University.|Key Laboratory of Medical Protection for Electromagnetic Radiation, Ministry of Education of China, Chongqing 400038, PR China.
Wenbin
W
Liu
Department of Pathology, Daping Hospital, Third Military Medical University, Chongqing, China.
Hualiang
H
Xiao
Institute of Toxicology, College of Preventive Medicine, Third Military Medical University.|Key Laboratory of Medical Protection for Electromagnetic Radiation, Ministry of Education of China, Chongqing 400038, PR China.
Yan
Y
Dong
Institute of Toxicology, College of Preventive Medicine, Third Military Medical University.|Key Laboratory of Medical Protection for Electromagnetic Radiation, Ministry of Education of China, Chongqing 400038, PR China.
Lei
L
Sun
Department of Pathology, Daping Hospital, Third Military Medical University, Chongqing, China.
Chengyi
C
Mao
Institute of Toxicology, College of Preventive Medicine, Third Military Medical University.|Key Laboratory of Medical Protection for Electromagnetic Radiation, Ministry of Education of China, Chongqing 400038, PR China.
Li
L
Yin
Institute of Toxicology, College of Preventive Medicine, Third Military Medical University.|Key Laboratory of Medical Protection for Electromagnetic Radiation, Ministry of Education of China, Chongqing 400038, PR China.
Xiao
X
Jiang
Institute of Toxicology, College of Preventive Medicine, Third Military Medical University.|Key Laboratory of Medical Protection for Electromagnetic Radiation, Ministry of Education of China, Chongqing 400038, PR China.
Lin
L
Ao
Institute of Toxicology, College of Preventive Medicine, Third Military Medical University.|Key Laboratory of Medical Protection for Electromagnetic Radiation, Ministry of Education of China, Chongqing 400038, PR China.
Zhihong
Z
Cui
Institute of Toxicology, College of Preventive Medicine, Third Military Medical University.|Key Laboratory of Medical Protection for Electromagnetic Radiation, Ministry of Education of China, Chongqing 400038, PR China.
Jia
J
Cao
Institute of Toxicology, College of Preventive Medicine, Third Military Medical University.|Key Laboratory of Medical Protection for Electromagnetic Radiation, Ministry of Education of China, Chongqing 400038, PR China.
Jinyi
J
Liu
D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology*; D000077192:Adenocarcinoma of Lung; D017209:Apoptosis; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000473:pathology; D002453:Cell Cycle; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology*; D008198:Lymph Nodes / Q000378:metabolism / Q000473:pathology; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D055747:SOX Transcription Factors / Q000378:metabolism*; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
D055747:SOX Transcription Factors; C000610511:SOX30 protein, human; D025521:Tumor Suppressor Proteins